bioTheranostics, a bioMerieux company developing oncology diagnostic tests to support targeted disease management, has presented new findings from a clinical study evaluating the company's Breast Cancer Index (BCI) molecular oncology test.
The BCI is a combination of HOXB13:IL17BR (H/I) and Molecular Grade Index (MGI), biomarkers that improve risk stratification in patients with estrogen receptor (ER)-positive, lymph-node negative breast cancer.
bioTheranostics said the BCI is available to provide quantitative assessment of the risk of distant disease recurrence and the risk assessment is based on data from a recently completed large, randomized, retrospective trial, MA.17 study.
The MA.17 study evaluated the role of adjuvant endocrine therapy with letrozole in reducing the risk of recurrence and improving disease-free survival among women with breast cancer who completed five years of tamoxifen therapy.
The data from the study demonstrate that BCI is a prognostic biomarker for late recurrence among ER-positive breast cancer patients and also confirm that HOXB13, part of the BCI, predicted patient benefit from letrozole among ER-positive breast cancer patients.
bioTheranostics CEO Richard Ding said the results presented in San Antonio become part of a substantial and growing body of data supporting the clinical value of the Breast Cancer Index.
"We are pleased to make this valuable test available to oncologists and pathologists in an enhanced format with clinical data specific for late breast cancer recurrence," Ding said.